CEL-SCI Corporation
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $28.3M
- Price
- $1.46
- % Change (Daily % change from the live per-ticker quote feed.)
- -10.37%
- Volume
- 183.5K
About
CEL-SCI Corporation (CVM) focuses on the research and development of immune-based therapies to combat cancer and various infectious diseases. Its flagship immunotherapy candidate, Multikine, is currently undergoing Phase III clinical trials for the treatment of head and neck cancer. The company also develops and holds the patent for its preclinical Ligand Epitope Antigen Presentation System (LEAPS), an innovative T-cell modulation technology. This system is designed to stimulate the human immune system to fight a broad range of conditions, including bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and various cancers. CEL-SCI's pipeline further includes LEAPS-H1N1-DC, along with LEAPS COV-19, an experimental therapy targeting the COVID-19 coronavirus. Additionally, the company is advancing CEL-2000 and CEL-4000 as potential treatments for rheumatoid arthritis. In a collaborative effort, CEL-SCI has partnered with the University of Georgia's Center for Vaccines and Immunology to progress the LEAPS COVID-19 immunotherapy. Established in 1983, the company's headquarters are located in Vienna, Virginia.
Quick stats
Shares outstanding17.5M
Computed float8.2M
Float / shares46.6%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000725363
Websitehttps://cel-sci.com
AI Summary
AI-generated1/25
majorbullishearnings
CEL-SCI Reports Fiscal Third Quarter 2026 Results
CEL-SCI reported a fiscal Q3 net loss of $5.7 million, or $0.47 per share, narrowing from the prior year, while raising $9.7 million in gross proceeds during the quarter.
The company published peer-reviewed biomarker data in Oral Oncology identifying patients with low or zero PD-L1 expression, confirming a targeted strategy for a 212-patient confirmatory registration study where Multikine demonstrated a 73% five-year survival rate versus 45% for standard of care.
A strategic partnership with Amarox was signed to pursue regulatory approval and commercialization in Saudi Arabia, targeting a Breakthrough Medicine Designation with a 50/50 net revenue share.